Oxford Target Therapeutics, a company developing a promising therapy for triple negative breast cancer, is one of three UK life science companies awarded research prizes by the Rosalind Franklin Institute, based in Oxfordshire, UK.
The prizes, awarded in collaboration with the Science and Technology Facilities Council (STFC), a part of UKRI, enable the winners to benefit from the Franklin’s top-level technologies and support to move their work forward.
The residency prizes, which include bench space, consumables and instrument time, are valued at between £30,000-£50,000.
Oxford Target Therapeutics plans to use the Franklin’s serial focused ion beam scanning electron microscopy to find out how its treatment acts on a micromolecular level on both breast cancer cells and healthy cells.
Victor Bolanos-Garcia, Founder and Chief Scientific Officer, said: “Without this opportunity, we wouldn’t be able to fund the cost of this work ourselves as we have too many competing priorities. But it is instrumental for us, so the Franklin’s offer of funding and expertise will really fill a vital gap.”
The results of the research will help the company plan more effective strategies to treat triple negative breast cancer, one of the most aggressive and deadly forms of the disease.
Pushing life sciences forward
The other winning biotech companies Neuro-Bio and Hypha Discovery plan to investigate, respectively, a potential early diagnostic test for Alzheimer’s disease and new technologies for determining the chemical structures of small drug metabolites.
Professor Ben Davis, Interim Director of the Rosalind Franklin Institute, said: “The Franklin is tasked with creating advances which push forward life science. The creative challenges posed by these SMEs are a great testbed for our technologies – this creates a golden opportunity to explore new areas together and so provide the companies with the leaps in results they need to take their products to the next stage.”
Image shows: Dr Maud Dumoux, the Franklin, and Dr Victor Bolanos-Garcia, Oxford Target Therapeutics.